Company Overview of CareDx, Inc
CareDx, Inc, a commercial stage company, develops, markets, and delivers diagnostic surveillance solutions for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient’s lifetime. Its commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a blood-based test used to monitor heart transplant recipients for acute cellular rejection. The company markets its AlloMap solution to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators, and nurse practitioners in the United States, Canada, and Europe. The company was formerly known as XDx...
3260 Bayshore Boulevard
Brisbane, CA 94005
Founded in 1998
Key Executives for CareDx, Inc
Chief Executive Officer, President and Director
Total Annual Compensation: $547.6K
Chief Medical Officer and Executive Vice President
Total Annual Compensation: $524.5K
Chief Compliance Officer and Chief Business Officer
Total Annual Compensation: $445.5K
Compensation as of Fiscal Year 2014.
CareDx, Inc Key Developments
CareDx, Inc. Announces First Patients Enrolled in Largest-Ever Multicenter Kidney Transplant Study Using Cell-Free DNA Technology
May 4 15
CareDx Inc. announced that the Cleveland Clinic has enrolled the first patients into a multicenter observational study designed to demonstrate the clinical performance characteristics of circulating cell-free DNA (cfDNA) in detecting clinical and sub-clinical rejection in kidney allograft recipients. The study is also designed to demonstrate the correlation of circulating cfDNA to renal function, both serum creatinine and estimated glomerular filtration rate. The Circulating Donor-Derived Cell-Free DNA in blood for diagnosing Acute Rejection in Kidney Transplant Recipients (DART) study is a prospective, multicenter, observational study of de-novo kidney transplant subjects where blood specimens will be drawn periodically after transplant and also after treatment for acute rejection. The first phase of the DART study is expected to enroll 200 patients in at least ten centers over a minimum of 18 months. A second phase of the DART study, to establish clinical utility, is expected to commence after initial results are obtained from the first phase.
CareDx, Inc - Shareholder/Analyst Call
Apr 16 15
CareDx, Inc - Shareholder/Analyst Call
CareDx, Inc Announces Financial Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Revenue Guidance for the Full Year of 2015
Mar 17 15
CareDx Inc. announced financial results for the fourth quarter and year ended December 31, 2014. Revenue for the three months ended December 31, 2014 increased 36% to $8.0 million, from $5.9 million in the same period in 2013. Of the $8.0 million in revenue, $1.1 million was associated with the payments from LabCorp. For the fourth quarter of 2014, net loss was $5,000 and basic and diluted net income per share was $0.00, compared to $562,000 or $0.56 per diluted share a year ago. Income from operations was $429,000 compared to $509,000 a year ago. Loss before income taxes was $5,000 compared to $562,000 a year ago.
For the full year 2014, revenues were $27.3 million versus $22.1 million in 2013, an increase of 24%. Net income for fiscal year 2014 was $781,000 compared to a net loss of $3.5 million for fiscal year 2013. Basic and diluted income per share were $0.13 and $0.10 for fiscal year 2014 compared to a $3.50 loss for both basic and diluted earnings per share for fiscal year 2013. Income from operations was $1,250,000 compared to loss of $857,000 a year ago. Loss before income taxes was $719,000 compared to $3,542,000 a year ago.
The company is providing revenue guidance for the full year of 2015. Revenue is expected to be in the range of $28 million to $30 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
January 30, 2015
May 21, 2014